Clinical Trials

The purpose of this study is to assess the acceptability, feasibility, and preliminary effectiveness of implementing a 30-day digitally-enabled community health worker intervention compared to usual care with a community health worker in reducing heart failure 30-day readmissions within a pilot randomized controlled trial.

The primary objective of this study is to determine if the correction of functional iron deficiency by administering a single dose of intravenous iron (ferric derimaltose or Monoferric®) in participants with heart failure with preserved ejection fraction (HFpEF) will improve exercise capacity as measured by the change in peak oxygen uptake (peak VO2) from baseline to 12 weeks.

In this study, the investigators will recruit a cohort of elderly Black and Hispanic patients with heart failure to define the number of patients who have cardiac amyloidosis by utilizing highly sensitive heart imaging and blood tests.

The purpose of this study is to assess the acceptability, feasibility, and preliminary effectiveness of implementing a 30-day digitally-enabled community health worker intervention compared to usual care with a community health worker in reducing heart failure 30-day readmissions within a pilot randomized controlled trial.

this study will determine whether dietary protein supplementation helps to prevent muscle wasting and will advance understanding of the GDF-15 and ActRII muscle wasting pathways.

HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes to help develop more personalized treatments for patients, with the hope that this will improve the lives of heart failure patients. To do this, HeartShare is bringing together a large amount of data (including images, such as heart ultrasounds and MRIs and molecular data from the blood, such as genetics) from previously conducted studies and electronic health records, and is gathering new data through participants enrolled in the HeartShare Deep Phenotyping Study.

Do you want to help find new treatments for heart failure with preserved ejection fraction? This study is testing whether a medicine called spironolactone can help treat heart failure with preserved ejection fraction when paired with the standard treatment. Spironolactone helps to remove excess water and sodium from the body. To participate in this study, you must be between 50 and 99 years old and diagnosed with heart failure with preserved ejection fraction.

Are you an adult planning to have heart surgery at Brigham and Women’s Hospital or Texas Heart Institute? This study is looking into the genetic causes of heart problems that can happen after heart surgery, such as atrial fibrillation, myocardial infarction, renal dysfunction, and heart failure. To participate in this study, you must be between 20 and 90 years old. This study takes place in Boston, Massachusetts; and Dallas and Houston, Texas.

Do you have heart failure and feel that your condition is harming your mental and physical well-being? This study is testing the use of an intervention called positive psychology–motivational interviewing (PP-MI). Researchers are exploring whether this 12-week intervention delivered by phone and text message can improve the physical and mental health of people with heart failure. To participate in this study, you must be at least 18 years old. This study takes place in Boston, Massachusetts.

Are you a current patient at Massachusetts General Hospital or Brigham and Women’s Hospital with clinical depression and heart failure or unstable chest pain (called angina)? This study is investigating whether 26 weeks of education and increased monitoring from healthcare managers improves psychiatric and heart symptoms better than self-managed care. This study takes place in Boston, Massachusetts.